CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions

被引:179
作者
Marrelli, Daniele [1 ]
Caruso, Stefano [1 ]
Pedrazzani, Corrado [1 ]
Neri, Alessandro [1 ]
Fernandes, Eduardo [3 ]
Marini, Mario [2 ]
Pinto, Enrico [1 ]
Roviello, Franco [1 ]
机构
[1] Univ Siena, Dept Human Pathol & Oncol, Unit Surg Oncol, I-53100 Siena, Italy
[2] Univ Siena, Gastroenterol Unit, I-53100 Siena, Italy
[3] Hammersmith Hosp, Imperial Coll Healthcare Trust, Renal Dept, Transplant Unit, London, England
关键词
Tumor marker; CA19-9; Obstructive jaundice; Pancreato-biliary malignancy; Endoscopic retrograde cholangiopancreatography; PRIMARY SCLEROSING CHOLANGITIS; TUMOR-MARKER CA19-9; PANCREATIC-CANCER; BILIARY DISEASES; CA-19-9; LEVELS; CA; 19-9; CEA; CARCINOMA; DIAGNOSIS; ANTIGEN;
D O I
10.1016/j.amjsurg.2008.12.031
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Obstructive jaundice is frequently associated with false CA19-9 elevation in benign conditions. The diagnostic accuracy of this tumor marker was evaluated in the present longitudinal study. METHODS: In 128 patients admitted for obstructive jaundice (87 with pancreato-biliary malignancy and 41 benign disease) serum CA19-9 was measured. Statistical analysis of marker levels obtained before and after endoscopic biliary drainage was performed in 60 patients. RESULTS: Elevated CA19-9 levels (>37 U/mL) were found in 61% of benign cases and 86% of malignancies. After biliary drainage, decrease of serum CA19-9 was observed in 19 of 38 malignant cases and in almost all benign cases (Wilcoxon matched pairs test: P = .207 and P < .001, respectively). Receiver operating characteristic (ROC) analysis identified a cut-off value of 90 U/mL to be associated with improved diagnostic accuracy after biliary drainage (sensitivity 61%, specificity 95%). CONCLUSIONS: In the presence of successfully drained obstructive jaundice, CA19-9 serum levels that remain unchanged or measure more than 90 U/mL are strongly indicative of a malignant cause of obstruction. However, the real clinical utility of this marker remains controversial. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 34 条
[1]   ELEVATED SERUM LEVELS OF TUMOR-MARKER CA19-9 IN ACUTE CHOLANGITIS [J].
ALBERT, MB ;
STEINBERG, WM ;
HENRY, JP .
DIGESTIVE DISEASES AND SCIENCES, 1988, 33 (10) :1223-1225
[2]  
Barone D, 1988, Int J Biol Markers, V3, P95
[3]   EXTRAHEPATIC CHOLESTASIS DETERMINES A REVERSIBLE INCREASE OF GLYCOPROTEIC TUMOR-MARKERS IN BENIGN AND MALIGNANT DISEASES [J].
BASSO, D ;
MEGGIATO, T ;
FABRIS, C ;
PLEBANI, M ;
FOGAR, P ;
PANOZZO, MP ;
DELFAVERO, G .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (12) :800-804
[4]   Basic concepts of statistical analysis for surgical research [J].
Cassidy, LD .
JOURNAL OF SURGICAL RESEARCH, 2005, 128 (02) :199-206
[5]  
Dorizzi RM, 2001, ACTA ONCOL, V40, P877
[6]   CA 19-9 as a marker for gastrointestinal cancers: a review [J].
Duffy, MJ .
ANNALS OF CLINICAL BIOCHEMISTRY, 1998, 35 :364-370
[7]   CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice [J].
Duraker, Nuevit ;
Hot, Semih ;
Polat, Yuecel ;
Hoebek, Anil ;
Gencler, Nur ;
Urhan, Nuray .
JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (02) :142-147
[8]   Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma [J].
Ferrone, Cristina R. ;
Finkelstein, Dianne M. ;
Thayer, Sarah P. ;
Muzikansky, Alona ;
Fernandez-del Castillo, Carlos ;
Warshaw, Andrew L. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2897-2902
[9]   Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer [J].
Goonetilleke, K. S. ;
Siriwardena, A. K. .
EJSO, 2007, 33 (03) :266-270
[10]   EVALUATION OF CA 19-9 AS A SERUM TUMOR-MARKER IN PANCREATIC-CANCER [J].
HAGLUND, C ;
ROBERTS, PJ ;
KUUSELA, P ;
SCHEININ, TM ;
MAKELA, O ;
JALANKO, H .
BRITISH JOURNAL OF CANCER, 1986, 53 (02) :197-202